Perirenal schwannoma: a case report
© El-Bahrawy et al; licensee BioMed Central Ltd. 2008
Received: 19 September 2007
Accepted: 02 June 2008
Published: 02 June 2008
Nerve sheath tumours of the kidney are particularly rare and, in the few reported cases, are all situated in the hilar region.
We describe the case of a tumour presenting towards the lateral border of the ventral aspect of the mid-zone of the kidney. This was a spindle cell lesion in which the cells strongly and diffusely expressed cytokeratins, but were negative for epithelial membrane antigen. The cells also expressed S-100 protein and glial fibrillary acidic protein, confirming the diagnosis of a cellular schwannoma.
To the best of our knowledge, this is the first case of a cellular schwannoma presenting towards the lateral border of the kidney. The case also highlights the importance of using a panel of antibodies in diagnosing spindle cell neoplasms in the kidney.
Schwannomas are encapsulated nerve sheath tumours that occur at all ages, but are most common between the ages of 20 and 50 years and affect both genders equally. The tumours have a predilection for the head, neck and flexor surfaces of the upper and lower extremities. Deeply situated tumours predominate in the posterior mediastinum and the retroperitoneum . A schwannoma is a slowly growing tumour that is usually present several years before diagnosis. Schwannomas behave in a benign fashion and malignant change is rare [2, 3].
A 55-year-old man presented with lower urinary tract symptoms in the form of hesitancy, poor stream and urgency. The patient did not have any flank and/or colicky pain. He had no history of urinary tract-related diseases or previous related illnesses and was constitutionally well with good appetite and normal body mass index. No abnormalities were detected on clinical examination.
Laboratory investigations revealed that serum prostate specific antigen was 5.1 ng/ml and serum creatinine was 86 μmol/l. Urine microscopy revealed no atypical cells and no haematuria. Prostate core biopsies showed benign prostatic hyperplasia.
The lesion was removed by laparoscopic partial nephrectomy with a small amount of renal parenchyma and surrounding fat with clear surgical margins as a curative approach. The specimen comprised a nodule surrounded by fat and attached with a small pedicle to a piece of renal tissue. The nodule was well-circumscribed, seemingly encapsulated, firm in consistency and measured 2.5 × 1.4 × 2.5 cm. The cut surface was grey-white with microcystic areas.
Immunostaining for a panel of cytokeratins was performed including broad range cytokeratins (AE1/AE3) and CK 7. The cells strongly and diffusely expressed cytokeratins on using a broad range cytokeratin cocktail, but were negative for CK7. The cells were also negative for epithelial membrane antigen (EMA). The tumour cells expressed S-100 protein and glial fibrillary acidic protein (GFAP) and were negative for HMB45, melan A, smooth muscle actin (SMA), desmin, CD34 and CD117. Immunostaining for Ki67 showed a very low index of less than 1% (Figure 2E–I).
The morphology and immunoprofile were characteristic of a cellular schwannoma.
A schwannoma is a benign nerve sheath tumour consisting of a highly ordered cellular component (Antoni A areas) and a loose myxoid component (Antoni B areas). Antoni A areas are composed of compact spindle cells that usually have wavy nuclei and indistinct cytoplasmic borders. The cells are arranged in interlacing fascicles and short bundles. In highly differentiated Antoni A areas, there may be nuclear palisading, whorling of the cells and Verocay bodies, formed by two compact rows of well-aligned nuclei separated by fibrillary cell processes. In Antoni B areas, the cells are arranged haphazardly in a loose matrix.
Cellular schwannoma is a rare variant of schwannomas, composed almost entirely of Antoni A areas that lack Verocay bodies. Small amounts of Antoni B may be present, usually not exceeding 10% of the lesion . Underneath their capsule they may contain lymphoid aggregates. Cellular schwannoma occurs in a similar age group as classic schwannoma but tends to develop more often in deep structures, such as the posterior mediastinum and retroperitoneum. Initial scepticism was expressed about the biological behaviour of cellular schwannomas, with some suggesting that it was in fact a low-grade malignant peripheral nerve sheath tumour (MPNST). Woodruff et al.  stressed the benign clinical course of cellular schwannomas and the importance of distinguishing them from MPNST. Subsequent studies have confirmed the benign nature of this tumour [6, 7].
We have reported the case of a renal schwannoma. To the best of the authors' knowledge, this is the first case of a schwannoma reported towards the lateral border of the kidney rather than in the hilar region. On microscopic examination, this was a cellular schwannoma and hence did not show the typical features of a classical schwannoma, including the Antoni A and Antoni B areas. On immunostaining, the cells showed diffuse and strong positivity for cytokeratins. Focal cytokeratin expression has been reported in schwannomas , but in this case, the cytokeratin expression using a broad range cytokeratin cocktail was strong and seen in all cells. However, the cells were all negative for cytokeratin 7 and EMA. The strong cytokeratin expression with the atypical histological features could have led to a diagnosis of an epithelial renal neoplasm as a sarcomatoid carcinoma.
S-100 protein has been shown to have a broad distribution in human tissues, including the renal tubules. Lin et al.  studied the expression of S-100 protein in primary and metastatic renal cell carcinoma (RCC) and non-neoplastic renal tissue. The results demonstrated the nuclear and cytoplasmic staining pattern for S-100 protein in 56 (69%) out of 81 conventional (clear cell) RCCs, 10 (30%) out of 33 papillary RCCs, 1 (6%) out of 16 chromophobe RCCs, and 13 (87%) out of 15 oncocytomas. Focal immunostaining was present in 22 (92%) out of 24 normal renal tubules. A similar staining pattern was observed in 21 (70%) out of 30 metastatic RCCs. Importantly, 14.8% (12 out of 81) of clear cell RCC and 13.3% (4 out of 30) of metastatic RCC revealed an immunostaining profile of pancytokeratin (-)/S-100 protein (+). These data indicate that caution should be taken in interpreting an unknown primary with S-100 positivity and cytokeratin negativity . This highlights the importance of using a panel of antibodies on handling a spindle cell lesion of the kidney to cover all of the possible differential diagnoses such as sarcomatoid carcinoma and synovial sarcoma in the context of the gross and histological features.
Different markers were used to exclude other spindle cell lesions. The markers for smooth muscle differentiation, desmin and SMA, were negative. Melan A and HMB45 were negative excluding a melanocytic lesion or an angiomyolipoma. CD34 and CD117 were used to exclude a gastrointestinal stromal tumour, whereas GFAP expression confirmed neural differentiation.
The patient presented with lower urinary tract symptoms, which were caused by benign prostatic hyperplasia, and the symptoms were not related to the renal neoplasm. The renal tumour was an incidental finding during routine investigations. There were no symptoms attributable to the lesion, which was completely asymptomatic. No flank pain and/or colic was ever experienced by the patient, and urine analysis did not show haematuria or atypical cells. The patient was constitutionally well, with a good appetite and normal body mass index and did not report any recent weight loss.
The differential diagnosis included RCC, therefore a curative approach was taken with laparoscopic partial nephrectomy including renal parenchyma with clear surgical margins.
A dimercaptosuccinic acid renal scan follow-up showed a differential renal function of 49% in the right kidney. Three years after the removal of the tumour the patient is well.
To the best of our knowledge, this is the first case of a renal schwannoma presenting towards the lateral border of the kidney. This was a cellular schwannoma, which showed, in addition to the expression of S-100 protein and GFAP, strong and diffuse expression of cytokeratins.
Renal schwannomas, although rare, must be considered in the differential diagnosis of spindle cell lesions of the kidney. We report a case of an incidentally identified perirenal schwannoma, which was treated by partial nephrectomy. In 1988, Somers et al.  reported a case of renal schwannoma recommending radical nephrectomy as the treatment of choice as then very few cases had been reported and the natural history and potential for malignancy was uncertain. Now given the benign clinical course of schwannomas, nephron-sparing surgery seems to be appropriate if technically feasible and the diagnosis is considered pre-operatively.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
epithelial membrane antigen
glial fibrillary acidic protein
malignant peripheral nerve sheath tumour
renal cell carcinoma
smooth muscle actin.
- Weiss SW, Goldblum JR: Benign Tumours of Peripheral Nerves. 2001, St. Louis, MO: MosbyGoogle Scholar
- Rasbridge SA, Browse NL, Tighe JR, Fletcher CD: Malignant nerve sheath tumour arising in a benign ancient schwannoma. Histopathology. 1989, 14: 525-528. 10.1111/j.1365-2559.1989.tb02189.x.View ArticlePubMedGoogle Scholar
- Nayler SJ, Leiman G, Omar T, Cooper K: Malignant transformation in a schwannoma. Histopathology. 1996, 29: 189-192. 10.1046/j.1365-2559.1996.d01-491.x.View ArticlePubMedGoogle Scholar
- Scheithauer BW, Woodruff JM, Erlandosn RA: Tumours of the Peripheral Nervous System. 1999, Washington, DC: American Registry of PathologyGoogle Scholar
- Woodruff JM, Godwin TA, Erlandson RA, Susin M, Martini N: Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor. Am J Surg Pathol. 1981, 5: 733-744.View ArticlePubMedGoogle Scholar
- Fletcher CD, Davies SE, McKee PH: Cellular schwannoma: a distinct pseudosarcomatous entity. Histopathology. 1987, 11: 21-35.View ArticlePubMedGoogle Scholar
- White W, Shiu MH, Rosenblum MK, Erlandson RA, Woodruff JM: Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors. Cancer. 1990, 66: 1266-1275. 10.1002/1097-0142(19900915)66:6<1266::AID-CNCR2820660628>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Ikeda I, Miura T, Kondo I, Kameda Y: Neurilemmoma of the kidney. Br J Urol. 1996, 78: 469-470.PubMedGoogle Scholar
- Somers WJ, Terpenning B, Lowe FC, Romas NA: Renal parenchymal neurilemmoma: a rare and unusual kidney tumor. J Urol. 1988, 139: 109-110.PubMedGoogle Scholar
- Ma KF, Tse CH, Tsui MS: Neurilemmoma of kidney – a rare occurrence. Histopathology. 1990, 17: 378-380. 10.1111/j.1365-2559.1990.tb00746.x.View ArticlePubMedGoogle Scholar
- Bezzi M, Orsi F, Rossi P: Nonencapsulated ancient schwannoma of the renal sinus. AJR Am J Roentgenol. 1996, 166: 1498.View ArticlePubMedGoogle Scholar
- Kitagawa K, Yamahana T, Hirano S, Kawaguchi S, Mikawa I, Masuda S, Kadoya M: MR imaging of neurilemoma arising from the renal hilus. J Comput Assist Tomogr. 1990, 14: 830-832. 10.1097/00004728-199009000-00034.View ArticlePubMedGoogle Scholar
- Tsurusaki M, Mimura F, Yasui N, Minayoshi K, Sugimura K: Neurilemoma of the renal capsule: MR imaging and pathologic correlation. Eur Radiol. 2001, 11: 1834-1837. 10.1007/s003300000767.View ArticlePubMedGoogle Scholar
- Fanburg-Smith JC, Majidi M, Miettinen M: Keratin expression in schwannoma; a study of 115 retroperitoneal and 22 peripheral schwannomas. Mod Pathol. 2006, 19: 115-121. 10.1038/modpathol.3800489.View ArticlePubMedGoogle Scholar
- Lin F, Yang W, Betten M, Teh BT, Yang XJ: Expression of S-100 protein in renal cell neoplasms. Hum Pathol. 2006, 37: 462-470. 10.1016/j.humpath.2005.12.008.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.